Year Founded
2017
Ownership
Private
Employees
~100
Therapeutic Areas
OphthalmologyNeurology
Stage
Other
Modalities
Induced pluripotent stem cells (iPSC)Stem cell therapyExosome therapy

Hopstem Biotechnology General Information

Lead candidate hNPC01 (iPSC-derived forebrain neural progenitor cell injection) received FDA IND clearance for ischemic stroke-related hemiplegia. First patient dosed in registration clinical trial in China.

Contact Information

Website
Primary Industry
[ "Biotech" ]
Corporate Office
Hangzhou, Zhejiang
China

Drug Pipeline

hNPC01
IND
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Hopstem Biotechnology's pipeline data

Book a demo

Key Partnerships

Xiangya Hospital

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Hopstem Biotechnology Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Hopstem Biotechnology's complete valuation and funding history, request access »